What is the safest way to adjust gliclazide modified‑release dosing for a type 2 diabetic patient who is fasting during Ramadan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Gliclazide MR Adjustment for Ramadan

For patients on gliclazide modified-release during Ramadan, take half the usual morning dose at the predawn meal (Suhoor) and the full dose at the sunset meal (Iftar), with no dose reduction needed for once-daily gliclazide MR formulations. 1

Pre-Ramadan Preparation (6-8 Weeks Before)

Conduct a structured risk assessment evaluating: 1

  • Current glycemic control (HbA1c levels)
  • Renal function (creatinine, eGFR)
  • Hepatic status (liver enzymes)
  • Complete biochemical profile

Patients on gliclazide MR alone or with metformin fall into the low-to-moderate risk category for fasting complications. 2

Specific Dosing Algorithm for Gliclazide MR

For Twice-Daily Gliclazide:

  • Predawn meal (Suhoor): Take 50% of the usual morning dose 1
  • Sunset meal (Iftar): Take 100% of the usual morning dose 1

For Once-Daily Gliclazide MR:

  • No dose reduction required 1
  • Simply shift timing from morning to evening (Iftar) 2, 3
  • Continue the same total daily dose throughout Ramadan 2

Managing Combination Therapy

If Combined with Metformin:

  • Two-thirds of total daily metformin dose immediately before Iftar (sunset meal) 1
  • One-third before Suhoor (predawn meal) 1

If Combined with Sulfonylureas:

  • Reduce other sulfonylurea doses by at least 50% or discontinue entirely 1
  • Never use chlorpropamide during Ramadan due to prolonged, unpredictable hypoglycemia risk 4, 1

Critical Monitoring Protocol

First 3-4 Weeks of Ramadan:

  • Check blood glucose in the first few hours after starting the fast each day 1
  • Recheck in late afternoon before breaking fast 1
  • Break the fast immediately if glucose drops below 70 mg/dL 5

Safety Data:

Real-world evidence demonstrates gliclazide MR during Ramadan results in: 2, 3

  • Only 1.0-2.2% incidence of symptomatic hypoglycemic events
  • Zero severe hypoglycemic events reported
  • Maintained or improved HbA1c control (-0.1 to -0.3%)
  • Stable or reduced body weight (-0.4 to -0.5 kg)

Nutritional Strategy

  • Distribute calories over 2-3 smaller meals during non-fasting hours rather than one large meal at Iftar 1
  • Maintain hydration with at least 1.5-2 L of water during non-fasting periods 5
  • Break the fast with a small, balanced meal containing fiber, protein, and complex carbohydrates 5

Critical Pitfalls to Avoid

Do not excessively reduce gliclazide dose beyond the recommended 50% reduction at Suhoor, as this may cause rebound hyperglycemia and increase diabetic ketoacidosis risk 1

Do not skip the pre-Ramadan assessment, as identifying high-risk patients and optimizing regimens prevents complications 1

Do not continue full-dose chlorpropamide or other long-acting sulfonylureas during Ramadan due to unacceptable hypoglycemia risk 4, 1

Post-Ramadan Management

  • Return gliclazide to the pre-Ramadan morning dosing schedule immediately after Ramadan ends 1
  • Reassess glycemic control, complications, and overall tolerance of fasting 1
  • Evaluate whether the patient can safely fast in future years based on outcomes 1

References

Guideline

Medication Management for Ramadan Fasting in Patients with Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Semaglutide During Ramadan Fasting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.